2017 Fiscal Year Final Research Report
Development of peptide-based cancer immunotherapy using tumor antigen-derived long peptides for oral cancer patients
| Project/Area Number |
16H07082
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-08-26 – 2018-03-31
|
| Keywords | 口腔がん / がん免疫療法 |
|---|
| Outline of Final Research Achievements |
In this study, to develop more effective cancer immunotherapy for oral cancer patients, we attempted to identify several HLA class II-restricted long peptides derived from some tumor antigens. We also tried to develop the biomarkers to predict the therapeutic effects of peptide-based cancer immunotherapy for oral cancer patients.
As a result, we identified several long peptides derived from cancer antigens, such as IMP-3, DEPDC1, and MPHOSPH1. Some of these peptide could activate both helper T cells and cytotoxic T cells, suggesting that these peptides are useful for exhibiting stronger anti-tumor immune responses. In addition, we identified T cells receptors of these tumor antigen-specific helper T cells.
|
| Free Research Field |
口腔がん
|
